Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Compass Pathways (NASDAQ: CMPS) has completed dosing all participants in Part A of its Phase 3 COMP005 trial, evaluating COMP360 psilocybin for treatment-resistant depression (TRD). The trial involved administering a single dose of either 25 mg COMP360 or placebo to participants following pre-dosing activities, including antidepressant medication washout where necessary.
The company remains on schedule to release top-line 6-week primary endpoint results in late June. This milestone represents significant progress in addressing unmet needs in treatment-resistant depression, demonstrating the company's commitment to scientific rigor and operational excellence in developing new treatment options for underserved patients.
Compass Pathways (NASDAQ: CMPS) has completed recruitment for its COMP005 phase 3 trial evaluating COMP360, a synthetic psilocybin treatment for treatment-resistant depression (TRD). Final participants are completing pre-dosing activities, including antidepressant medication washout where necessary.
The trial is part of the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Top-line results for the 6-week primary endpoint are expected in late Q2 2025, while 26-week data will be available after all participants complete part A of the COMP006 trial, expected in second half 2026.
COMP360 is being investigated as a potential first-in-class psilocybin treatment for mental health conditions, administered with psychological support. TRD affects patients who don't respond adequately to at least two different treatments, with up to one-third of depression patients failing multiple treatment attempts.
Compass Pathways (NASDAQ: CMPS) has published results from its COMP004 study, a 52-week observational follow-up of Phase 2 trials evaluating COMP360 psilocybin for treatment-resistant depression (TRD). The study demonstrated that a single 25mg dose of COMP360 maintained antidepressant effects longer compared to lower doses.
Key findings show the median time to depressive event was 92 days for the 25mg group, versus 83 days (10mg) and 62 days (1mg). A post-hoc analysis revealed even more substantial differences, with 189 days for the 25mg group compared to 43 days (10mg) and 21 days (1mg).
The treatment was generally well-tolerated, with three participants reporting treatment emergent serious adverse events deemed unrelated to the study drug. The company expects top-line data from its ongoing Phase 3 COMP005 trial in Q2 2025, with 26-week COMP006 data anticipated in H2 2026.
Compass Pathways (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced its upcoming participation in the Stifel Virtual CNS Forum. The company's management will deliver a presentation on March 18th, 2025 at 11:30 am ET.
The presentation will be available through a live audio webcast on the 'Events' page within the Investors section of Compass's website. Interested parties can access a replay of the webcast for up to 30 days after the event.
Compass Pathways (NASDAQ: CMPS) reported its Q4 and full-year 2024 financial results, highlighting ongoing progress in its clinical trials. The company's Phase 3 COMP005 trial for treatment-resistant depression (TRD) remains on schedule, with top-line data expected in Q2 2025.
Financial results show a net loss of $155.1 million ($2.30 per share) for 2024, compared to $118.5 million in 2023. R&D expenses increased to $119.0 million from $87.5 million, while G&A expenses rose to $59.2 million from $49.4 million.
The company's cash position stood at $165.1 million as of December 31, 2024, with an additional $140.4 million net cash raised in Q1 2025. Full-year 2025 net cash used in operating activities is projected between $120-145 million, with funding sufficient through the planned COMP006 26-week data readout in H2 2026.
Compass Pathways (Nasdaq: CMPS), a mental health-focused biotechnology company, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation on March 3rd, 2025, at 1:10 pm ET.
Investors and interested parties can access a live audio webcast of the presentation through the 'Events' page in the Investors section of the Compass website. The webcast recording will remain available for 30 days after the event.
Compass Pathways (NASDAQ: CMPS), a biotechnology company focused on mental health innovation, has announced it will release its Q4 and full-year 2024 financial results on February 27th, 2025. The company will host a conference call at 8:00 AM ET (1:00 PM UK) on the same day to discuss results and provide updates on recent developments. Investors can access the call through pre-registration, and a live webcast will be available on the company's website. The webcast recording will remain accessible for 30 days in the Investors section.
Compass Pathways (Nasdaq: CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The company's management will deliver a presentation on February 12th, 2025, at 8:40 am ET.
Interested parties can access a live audio webcast of the presentation through the 'Events' page in the Investors section of the Compass website. The webcast recording will remain available for 30 days after the event.
Compass Pathways (NASDAQ: CMPS) has appointed Steve Levine, M.D., as Chief Patient Officer in a newly created executive role. Dr. Levine, who has been with Compass since 2020 as Senior Vice President of Patient Access, will focus on embedding patient-centric strategies across the organization and ensuring treatments address unmet clinical care needs.
Dr. Levine is a board-certified psychiatrist with extensive experience in healthcare innovation and access. He previously founded Actify Neurotherapies, developing care delivery models for interventional psychiatry treatments. His academic background includes training at New York-Presbyterian Hospital/Weill Cornell Medical Center and Memorial Sloan Kettering Cancer Center. He currently serves as an adjunct professor at Rutgers Medical School.
Compass Pathways (NASDAQ: CMPS) has announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (ADSs) and pre-funded warrants for up to 11,044,720 ADSs. Each ADS and pre-funded warrant includes an ADS Warrant with an exercise price of $5.796, representing a 40% premium to the last sale price.
The offering price is set at $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and ADS Warrant. The offering, led by Deep Track Capital, is expected to generate gross proceeds of approximately $150 million, potentially reaching $353 million if all ADS Warrants are exercised.
The proceeds will fund ongoing Phase 3 trials in treatment-resistant depression (COMP005 and COMP006), with data expected in Q2 2025 and H2 2026, respectively. Additionally, funds will accelerate a late-stage PTSD development program and support working capital needs.